- Home
- AMIX vs PBM Comparison
AMIX vs PBM Comparison
Compare AMIX & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- PBM
- Stock Information
- Founded
- AMIX 2014
- PBM 1994
- Country
- AMIX United States
- PBM Canada
- Employees
- AMIX N/A
- PBM N/A
- Industry
- AMIX
- PBM
- Sector
- AMIX
- PBM
- Exchange
- AMIX NYSE
- PBM NYSE
- Market Cap
- AMIX 5.5M
- PBM 5.3M
- IPO Year
- AMIX N/A
- PBM N/A
- Fundamental
- Price
- AMIX $2.97
- PBM $1.30
- Analyst Decision
- AMIX
- PBM
- Analyst Count
- AMIX 0
- PBM 0
- Target Price
- AMIX N/A
- PBM N/A
- AVG Volume (30 Days)
- AMIX 58.5K
- PBM 367.3K
- Earning Date
- AMIX 02-13-2025
- PBM 02-02-2025
- Dividend Yield
- AMIX N/A
- PBM N/A
- EPS Growth
- AMIX N/A
- PBM N/A
- EPS
- AMIX N/A
- PBM N/A
- Revenue
- AMIX N/A
- PBM N/A
- Revenue This Year
- AMIX N/A
- PBM N/A
- Revenue Next Year
- AMIX N/A
- PBM N/A
- P/E Ratio
- AMIX N/A
- PBM N/A
- Revenue Growth
- AMIX N/A
- PBM N/A
- 52 Week Low
- AMIX $2.55
- PBM $1.15
- 52 Week High
- AMIX $93.80
- PBM $323.25
- Technical
- Relative Strength Index (RSI)
- AMIX 47.86
- PBM 38.56
- Support Level
- AMIX $2.76
- PBM $1.15
- Resistance Level
- AMIX $2.95
- PBM $1.47
- Average True Range (ATR)
- AMIX 0.16
- PBM 0.13
- MACD
- AMIX 0.08
- PBM 0.04
- Stochastic Oscillator
- AMIX 72.83
- PBM 34.09
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.